RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Genetic Determinants of Variability in Dabigatran Exposure
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 13
SP 21
OP 22
DO 10.1177/155989771213013
UL http://mdc.sagepub.com/content/12/13/21.abstract
AB Genetic factors may be responsible for some of the inter-individual variability in dabigatran exposure, according to findings from the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY] Genetics study. The RE-LY trial demonstrated that dabigatran 150 mg BID was superior to warfarin, while the 110 mg dose was noninferior to warfarin in the reduction of stroke in patients with atrial fibrillation [Connolly SJ et al. N Engl J Med 2009].